Anti-CD38 Antibody-drug Conjugate STI-6129 clinical trials
Also written STI-6129.
How each study uses Anti-CD38 Antibody-drug Conjugate STI-6129 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-CD38 Antibody-drug Conjugate STI-6129 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2023 (4)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
Sorrento Therapeutics, Inc. (4) · Zhejiang ACEA Pharmaceutical Co. Ltd. (1) · M.D. Anderson Cancer Center (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Anti-CD38 Antibody-drug Conjugate STI-6129.
- Dec 2026Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple MyelomaPhase 1/2 · Zhejiang ACEA Pharmaceutical Co. Ltd.
Studies
Open first, then newest update. How each study uses Anti-CD38 Antibody-drug Conjugate STI-6129 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple MyelomaRecruitingPhase 1/2Zhejiang ACEA Pharmaceutical Co. Ltd.NCT05565807Written as STI-6129How we know
- Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid TumorsNot yet recruitingPhase 1Sorrento Therapeutics, Inc.NCT05584709Written as STI-6129How we know
- STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL AmyloidosisWithdrawnPhase 1M.D. Anderson Cancer CenterNCT05519527Written as Part 1 (STI-6129)How we know
- An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL AmyloidosisWithdrawnPhase 1Sorrento Therapeutics, Inc.NCT05692908Written as STI-6129How we know
- Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple MyelomaActive, not recruitingPhase 1/2Sorrento Therapeutics, Inc.NCT05308225Written as STI-6129How we know
- Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL AmyloidosisStatus unknownPhase 1/2Sorrento Therapeutics, Inc.NCT04316442Written as STI-6129How we know